Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13059547 | 0.86 | ALDH1A1 (0.30) | KMT2AMEN1ALDH1A1NPSR1POLB | |
| SCHEMBL13002674 | 0.81 | ALDH1A1 (0.33) | SMN1; SMN2KMT2AMEN1ALDH1A1NPSR1 | |
| SCHEMBL13059536 | 0.78 | HTR2A (0.35) | SMN1; SMN2KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL10199736 | 0.76 | PDE4A (0.32) | SMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL10199684 | 0.74 | PDE4A (0.33) | SMN1; SMN2KMT2AMEN1ALDH1A1POLB | |
| SCHEMBL18567692 | 0.71 | KMT2A (0.34) | SMN1; SMN2KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL13002859 | 0.68 | NPC1 (0.32) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL13002839 | 0.67 | ACACB (0.37) | — | |
| SCHEMBL18753214 | 0.67 | ACACB (0.37) | — | |
| SCHEMBL13002769 | 0.67 | GABRG2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406216-B1 | HALOGENALKYLMETHYLENOXY-PHENYL-SUBSTITUTED KETOENOLS | BAYER IP GMBH (DE) | 2017-04-19 | — | — | EP | disclosed |
| EP-3153503-A1 | INTERMEDIATES FOR HALOGENOALKYLMETHYLENOXY-PHENYL-SUBSTITUTED KETOENOLS | Bayer Intellectual Property GmbH (DE) | 2017-04-12 | — | — | EP | disclosed |
| US-9045390-B2 | Haloalkylmethyleneoxyphenyl-substituted ketoenols | BAYER CROPSCIENCE AG (DE) | 2015-06-02 | — | — | US | disclosed |
| US-9045390-B2 | Haloalkylmethyleneoxyphenyl-substituted ketoenols | BAYER CROPSCIENCE AG (DE) | 2015-06-02 | — | — | US | disclosed |
| US-20140213813-A9 | Haloalkylmethyleneoxyphenyl-Substituted Ketoenols | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-31 | — | — | US | disclosed |
| US-20140213813-A9 | Haloalkylmethyleneoxyphenyl-Substituted Ketoenols | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-31 | — | — | US | disclosed |
| US-20140031577-A1 | Haloalkylmethyleneoxyphenyl-Substituted Ketoenols | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20140031577-A1 | Haloalkylmethyleneoxyphenyl-Substituted Ketoenols | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-8518985-B2 | Haloalkylmethyleneoxyphenyl-substituted ketoenols | BAYER CROPSCIENCE AG (DE) | 2013-08-27 | — | — | US | disclosed |
| US-8518985-B2 | Haloalkylmethyleneoxyphenyl-substituted ketoenols | BAYER CROPSCIENCE AG (DE) | 2013-08-27 | — | — | US | disclosed |
| US-20100311593-A1 | Haloalkylmethyleneoxyphenyl-substituted ketoenols | BAYER CROPSCIENCE AG (DE) | 2010-12-09 | — | — | US | disclosed |
| WO-2010102758-A2 | HALOGENALKYLMETHYLENOXY-PHENYL-SUBSTITUTED KETOENOLS | BAYER CROPSCIENCE AG (DE) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213813-A9 | Haloalkylmethyleneoxyphenyl-Substituted Ketoenols | PHYKPL, KCNE1, CSNK1E | NPC1 2885/4885RAB9A 4495/4885SMN1; SMN2 4677/4885 |
| US-20140031577-A1 | Haloalkylmethyleneoxyphenyl-Substituted Ketoenols | PHYKPL, KCNE1, CSNK1E | NPC1 2885/4885RAB9A 4495/4885SMN1; SMN2 4677/4885 |
| US-20100311593-A1 | Haloalkylmethyleneoxyphenyl-substituted ketoenols | PHYKPL, KCNE1, CSNK1E | NPC1 2885/4885RAB9A 4495/4885SMN1; SMN2 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.